CLOs on the Move


 
  • Number of Employees:
  • Annual Revenue:

  • ,

Executives

Name Title Contact Details

Similar Companies

Phillip Jeffries Ltd

Phillip Jeffries Ltd is a family-run company that specializes in the manufacture and importation of high-quality, unique, and textured wallcoverings. Founded in 1976 by Eric Bershad, the company has established itself as a global leader in the industry, offering an extensive range of over 1,000 natural wallcoverings. Their product lineup includes Japanese paper weaves, gold leaf, grasscloth, silks, and unique hand-crafted specialties, all crafted by skilled artisans to ensure exceptional quality and aesthetic appeal. The company is led by Eric Bershads sons, Philip and Jeffrey Bershad, who serve as President and Chief Executive Officer, respectively. This family involvement helps maintain the companys mission and values. Phillip Jeffries is known for its commitment to fast delivery, making it a preferred choice for interior designers, architects, and high-end homeowners seeking distinctive wallcovering solutions.

Florida Capital Bank

We bring the bank to you. We have been a part of the community since 2004 and take pride in being a locally-owned hometown bank. Our top priority is our customers satisfaction, and we have grown alongside the communities we serve. We pledge to offer modern banking convenience with old-fashioned hometown service. Our business is conducted locally, with local investors, a local Board of Directors, and local bankers making local decisions. FLCBank is a leader in the banking industry, focusing on solutions for the financial well-being of businesses and their owners. Headquartered in Jacksonville, Florida, we have branches in Gainesville, Jacksonville, Orlando, and Tampa Bay. We believe in fostering a friendly, fun, respectful, and caring culture throughout the organization, which naturally translates into how we treat our customers. We uphold high standards and provide services and products to our business and personal banking customers that align with our standards of excellence. We are proud recipients of Jacksonville Magazines annual Companies with Heart Award from 2017-2023. The Jacksonville Business Journal has also recognized us as one of the Best Places to Work for six years! Through our community involvement efforts, Florida Capital Bank provides meaningful support to organizations that help to make the communities we live and work in stronger and better for all citizens. Please note: Florida Capital Bank, N.A. or its designee reserves the right to remove any spam, unsolicited advertising, or inappropriate and offensive comments from our page

Lancaster County Motors, Inc.

Lancaster County Motors is an automotive sales and service company based in East Petersburg, Pennsylvania. Our dealerships include Lancaster County Motors Subaru, Lancaster Hyundai, Lancaster County Kia, Mercedes-Benz of Lancaster, Providence Autos, and LCM Used Cars.

IMUNON

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.